Comparative Pharmacology
Head-to-head clinical analysis: DELTASONE versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTASONE versus HYDROCORTISONE IN ABSORBASE.
DELTASONE vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, leading to altered gene expression and suppression of inflammatory mediators, immune cells, and cytokine production.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
5-60 mg orally once daily or divided twice daily; dose individualized based on condition and response.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
The terminal elimination half-life of prednisolone (active form) is 2.1–3.5 hours. In clinical context, this short half-life supports once-daily to twice-daily dosing for anti-inflammatory effects, but adrenal suppression can persist longer due to receptor binding.
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Prednisone is a prodrug converted to prednisolone. Prednisolone is metabolized primarily in the liver. Renal excretion of unchanged drug is negligible (<1%). Metabolites are excreted renally (approximately 80% as glucuronides and sulfates) and to a small extent in feces (<5%). Biliary excretion is minimal.
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid